USFDAAug 6, 2026, 07:38 AM
Viridian Therapeutics' Veligrotug Approved by FDA in June 2026
AI Summary
Viridian Therapeutics announced that its product, veligrotug (Lumvoa™), received FDA approval for Thyroid Eye Disease in June 2026, marking the company's first product sales revenue of $284k in Q2 2026. Despite reporting a net loss of $(127.1) million for the quarter, the company significantly bolstered its financial position by raising $250.0 million from convertible notes and $143.8 million from common stock offerings in the first half of 2026. Viridian ended Q2 2026 with $981.5 million in cash, cash equivalents, and marketable securities, which is expected to fund operations for at least the next twelve months.
Key Highlights
- FDA approved veligrotug (Lumvoa™) for Thyroid Eye Disease in June 2026.
- Generated first product sales revenue of $284k in Q2 2026.
- Reported a net loss of $(127.1) million for Q2 2026.
- Selling, general, and administrative expenses increased to $55.0 million in Q2 2026.
- Raised $250.0 million from convertible notes in the first half of 2026.
- Raised $143.8 million from common stock offerings in the first half of 2026.
- Ended Q2 2026 with $981.5 million in cash, cash equivalents, and marketable securities.
- Accumulated deficit reached $(1,570.5) million as of June 30, 2026.
Price Impact
More from VRDN